Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

in severity as treatment continues. Application site disorders were common (47 percent), but all were mild (44 percent) or moderate (4 percent) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57 percent) with PEGINTRON but similar to INTRON A (58 percent). Depression was most common at 29 percent. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1 percent of patients during or shortly after completing treatment with PEGINTRON.

PEGINTRON/REBETOL is contraindicated in patients with autoimmune hepatitis, decompensated liver disease, and in patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia).

The following serious or clinically significant adverse events have been reported at a frequency less than 1 percent with PEGINTRON or interferon alpha: severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial the incidence of serious adverse events was 17 percent in the PEGINTRON/REBETOL groups compared to 14 percent in the INTRON A/REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23 percent in the INTRON A/REBETOL group and 31-34 percent in the PEGINTRON/R
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 1 Allen Medical Systems, a Hill-Rom company, (NYSE: ... Spotlight Series showcasing interviews with top orthopaedic surgeons. Carlos ... Institute, is the featured surgeon and is recognized for ... Intraoperative Arm Positioner for elbow fractures, scopes and clavicle ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE), a ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, announced today that Patrick T. Mooney, M.D., Chairman ... Annual JMP Securities Healthcare Conference on Tuesday, October 6, ...
Cached Medicine Technology:Allen Medical Systems Announces Surgeon Spotlight Series Interview 2Allen Medical Systems Announces Surgeon Spotlight Series Interview 3Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 2
(Date:7/10/2014)... CLEVELAND The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization. ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) ... quality of life. Some patients have disturbed sleep/wake ... asleep, while other patients may be subject to ... extreme, PD patients may exhibit REM-sleep behavior disorder ... re-enactment, even before motor symptoms appear. A review ...
(Date:7/10/2014)... Katerina Alba,s research at the University of Huddersfield could ... most popular emulsion-based food products such as butter, ... starting to gain an international profile for her work. ... food science at the University and now she has ... her supervisor, Dr Vassilis Kontogiorgos, she is investigating the ...
(Date:7/10/2014)... 10, 2014) A research review identifying the clinical ... first step in the process of developing evidence-based guidelines ... new report published by Neurosurgery , ... Surgeons . The journal is published by Lippincott ... Wolters Kluwer Health . , Based on analysis ...
(Date:7/10/2014)... Spring Harbor, NY For decades, health-conscious people around ... rich in antioxidants, figuring this was one of the ... , Yet clinical trials of antioxidant supplements have ... hoping to reduce their cancer risk. Virtually all ... against cancer. In fact, in several trials antioxidant ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2
... and amoxicillin when it comes to treating ailments like ... effective. Doctors, who reviewed the treatment given to // ... the newer drugs is more effective than the traditional ... ,Pediatricians at the University of Rochester Medical Center found ...
... treatment by Andrew Lamerton, a vascular surgeon, until he ... lead to the patient being confined to a wheelchair. ... only aggravated Smith’s condition, and he would feel better ... County Hospital supported the doctor, as the National Institute ...
... A new research has revealed that happiness results ... The Psychological Bulletin of the American Psychological Association ... reinforcing positive emotions, which also motivates people to ... ,Dr. Sonja Lyubomirsky of the University ...
... awareness regarding beauty and body solutions, the demand for ... steadily over the recent years. The healthy competition amongst ... has not only resulted in improved outcomes but also ... was previously underdeveloped when compared to the other Indian ...
... during the course of the winter and fall months, from ... to overcome the seasonal affective disorder (SAD), and the people ... ,Those who suffer from SAD overeat, sleep a lot, and ... and develop an aversion to social interactions. The lesser sunlight ...
... anti-inflammatory drug Bextra, meant for those who suffer from arthritis. ... cardiovascular risks, including the possibility of // triggering strokes and ... ,The drug is also known to cause severe skin ... earlier withdrawn the drug which belongs to the cox-2 inhibitors ...
Cached Medicine News:Health News:Penicillin To Pave Way For New Antibiotics 2Health News:Happiness Plays An Important Role In Success 2Health News:New Plastic Surgery Unit Set Up In Kolkata To Meet Ever-Increasing Consumer Demand 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: